IHC Her2 scores were obtained per routine clinical care using the Hercept Test kit from DAKO.[6 (link)] (Supplementary Figure 1,2
Hercept test kit
Manufactured by Agilent Technologies
The Hercept Test kit is a laboratory equipment product designed for the detection and quantification of the HER2 protein in breast cancer tissue samples. It is a diagnostic tool used to assist healthcare professionals in the assessment and management of breast cancer patients.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using hercept test kit
1
HER2 Immunohistochemistry Protocol
2
Evaluating HER2 Status in Gastric Cancer Biopsy
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The tumor biopsy specimens obtained prior to chemotherapy were subjected to immunohistochemistry (IHC) analysis. All paraffin-embedded specimens were cut into 4-µm-thick slices and transferred to a slide. IHC was conducted using the Hercept test kit (Dako, Carpinteria, CA) based on the protocol recommended by the manufacturer. According to the Hercept test scoring criteria, staining intensity was scored as 0, 1 + , 2 + , or 3 + [3 (link)].
Fluorescence in situ hybridization (FISH) was conducted using the Abbott PathVysion HER2 DNA Probe Kit protocol (Abbott Laboratories, Abbott Park, Des Plaines, IL) according to the manufacturer’s instructions. HER2 gene amplification was assessed by calculating the number of HER2 and centromere enumerator probe 17 (CEP 17) signals in 20 adjacent interphase tumor cell nuclei, which were examined under a fluorescent microscope with the appropriate filters. A positive HER2 gene amplification status was defined as a HER2:CEP17 ratio of ≥ 2.0 [3 (link)].
In the present study, patients who had tumors with an IHC score of 3 + or an IHC score of 2 + plus FISH positivity were defined as having HER2-positive gastric cancer [3 (link)].
Fluorescence in situ hybridization (FISH) was conducted using the Abbott PathVysion HER2 DNA Probe Kit protocol (Abbott Laboratories, Abbott Park, Des Plaines, IL) according to the manufacturer’s instructions. HER2 gene amplification was assessed by calculating the number of HER2 and centromere enumerator probe 17 (CEP 17) signals in 20 adjacent interphase tumor cell nuclei, which were examined under a fluorescent microscope with the appropriate filters. A positive HER2 gene amplification status was defined as a HER2:CEP17 ratio of ≥ 2.0 [3 (link)].
In the present study, patients who had tumors with an IHC score of 3 + or an IHC score of 2 + plus FISH positivity were defined as having HER2-positive gastric cancer [3 (link)].
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!